An early-stage drug for a coronary heart illness known as ATTR-CM confirmed potential to reverse illness development, opening up a brand new manner of attacking the situation as present medicine have been designed to solely sluggish or stall the illness.
In a small Section 1 trial, the drug, a monoclonal antibody named NI006, appeared to cut back dangerous protein buildup within the coronary heart based mostly on imaging, in response to the examine, revealed Saturday within the New England Journal of Drugs.
The treatment was initially developed by Neurimmune and has been licensed to Alexion, the uncommon illness unit of AstraZeneca. Given the outcomes, researchers plan to advance the drug instantly right into a Section 3 trial, stated Martin Cowie, medical vp of cardiovascular and coronary heart failure R&D at AstraZeneca.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED